•  
  •  
  •  
  •  

2026-08-12 12:20:59

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT

Keywords Selected:  SyngeneInternational

Research

  • Q4FY22 Result Update - Syngene International - ICICI Direct
  • Q3FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Q3FY22 Result First cut - YES Securities
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

Stock Report

  • Siddharth Mittal Appointed as Managing Director & CEO of Syngene International
  • Syngene International Ltd consolidated Q4FY26 profit up QoQ at Rs. 147.9 crores
  • Syngene International Ltd recommends final dividend of Rs. 1.25
  • Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035
  • Syngene International Ltd Q2FY26 consolidated PAT declines to Rs. 67.1 crores
  • USFDA conducts GCP inspection at Syngene International Ltd's facility at Semicon Park, Bengaluru
  • Syngene International Ltd updates on USFDA inspection at Biocon Park, SEZ, Bengaluru
  • Syngene International Ltd recommends final dividend of Rs. 1.25
  • Syngene International Ltd Q4 FY2025 consolidated profit at Rs. 183.3 crores
  • Syngene International Limited appoints Mr. Peter Bains as MD & CEO
  • Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc.
  • Syngene acquires its First Manufacturing Facility in the US
  • Syngene International Ltd updates on USFDA inspection at Bengaluru facilities
  • Syngene International Ltd consolidated Q3FY25 profit up at Rs. 131.1 crores
  • Syngene International Ltd Q2 FY2025 consolidated PAT at Rs. 106.1 crores
  • Syngene International Ltd Q1 FY2024-25 consolidated net profit declines to Rs. 75.7 crores
  • Syngene International Ltd recommends final dividend of Rs. 1.25
  • Syngene International Ltd reports Rs. 188.6 crores consolidated PAT in Q4 FY2024
  • Syngene International Ltd consolidated Q3 FY2024 net profit at Rs. 111.5 crores
  • Syngene concludes the acquisition of biologics manufacturing facility from Stelis Biopharma Ltd
  • Syngene International Ltd Q2 FY2024 consolidated PAT higher at Rs. 116.5 crores
  • Syngene International Ltd posts consolidated PAT of Rs. 93.4 crores in Q1 FY2024
  • Stelis Biopharma enters into a binding term sheet with Syngene International Ltd to divest its Unit 3 multi-modal facility
  • Syngene International Ltd recommends final dividend of Rs. 1.25

Latest Post

  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025